Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 19, 2025
Daily News
May 19, 2025
- Impact of US Drug Policy: President Trump Shaking the World of Pharma
May 19, 2025
- Japan’s Big 4 Wholesalers Log Operating Margin of 1.24%, All Break 1% Mark: Tally
May 19, 2025
- At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
May 19, 2025
- Sawai Wins Lawsuit over CML Use in Sprycel Generic
May 19, 2025
- Boehringer Ingelheim, Kanagawa Join Hands in Disease Prevention
May 19, 2025
- AstraZeneca, Nara City Form Partnership in NCDs
May 19, 2025
- Seikagaku Eyes FDA Re-Filing of Herniated Disk Drug within 1 Year
May 19, 2025
- PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action
May 19, 2025
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…